Immunisation against hepatitis B has been offered to hospital staff who are at risk of contracting the disease for several years now. Initially a plasma derived vaccine was used but since 1987 recombinant hepatitis B vaccine has been available in the United Kingdom and has come to be the preferred choice. The rate of seroconversion after three doses of the vaccine is said to be high, although the rate of conversion seems to decrease with increasing age'2 and may be lower when the vaccine is given into the buttock rather than into the deltoid muscle. About a third (30 3%) had two doses of the plasma derived vaccine and one dose of the recombinant vaccine; a much smaller number (7 4%) had one dose of the plasma derived and two doses of recombinant and the remainder had three doses of recombinant vaccine. Antibody levels after vaccination were measured by an enzyme immunoassay method and the results expressed in mIU/ml. Levels greater than 10 mIU/ml were considered to show a positive response, those below this, a negative response. Using this criterion, only 30 of the 769 individuals in the study (4 0%) showed no antibody response at all or had levels less than 10 mIU/ml. A substantial majority had levels greater than 120 mIU/ml (645, or 84 8%); the response rate did not differ appreciably whichever combination of vaccine was given. The cumulative frequency of the different antibody responses is shown in the figure.
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There seemed to be no characteristics that distinguished the responders from the non-responders (table) . There were rather more women than men and more were under 30 than over 40; in this they reflect the general characteristics of the staff who have been vaccinated in the health district.
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These results, and those of Cockcroft 
